Stock listing

NASDAQ:VRAX Virax Biolabs Group Limited Stock

Home listing (NASDAQ) of Virax Biolabs Group Limited

Follow Virax Biolabs Group Limited into a list and get an email when it puts out news.

Share price · NASDAQ:VRAX

$0.332 USD -0.049 (-12.9%)

Close on Nov 20, 2026

Past year -96.7% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$0.327 – $0.370 USDNov 20, 2026
Volume
85,897 sharesNov 20, 2026
Market cap
$446,402 USDAt the close on Nov 20, 2026 · price × 1.34M shares outstanding
52-week range
$0.293 – $21.750 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$510,091 USDMedian day 39,950 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Virax Biolabs Group Limited logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:VRAX · Home$0.332 USD-0.049 (-12.9%)85,897$0.370$0.370$0.327$0.381Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:VRAX · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$0.332-0.049-12.9%$0.370$0.370$0.32785,897
$0.381-0.049-11.4%$0.436$0.460$0.293257,162
$0.430-0.015-3.4%$0.448$0.495$0.410376,790
$0.445-0.003-0.6%$0.435$0.470$0.410128,524
$0.448-0.165-26.9%$0.510$0.550$0.400182,622
$0.613-0.055-8.2%$0.667$0.685$0.601124,100
$0.668+0.041+6.5%$0.627$0.696$0.60080,300
$0.627-0.017-2.6%$0.625$0.670$0.550225,700
$0.644-0.066-9.3%$0.630$0.700$0.503256,800
$0.710-0.082-10.4%$0.810$0.810$0.646344,500
$0.792-0.388-32.9%$0.970$0.990$0.6301,094,700
$1.180-0.020-1.7%$1.330$1.349$1.0103,710,600
$1.200+0.140+13.2%$1.160$1.570$1.11010,978,300
$1.060-0.040-3.6%$1.090$1.175$1.04033,700
$1.100-0.110-9.1%$1.170$1.180$1.10024,200
$1.210-0.110-8.3%$1.285$1.300$1.18023,600
$1.320+0.120+10.0%$1.300$1.330$1.23557,900
$1.200+0.010+0.8%$1.170$1.210$1.16010,100
$1.1900.0000.0%$1.230$1.230$1.14011,900
$1.190-0.030-2.5%$1.260$1.260$1.18010,500
$1.220-0.015-1.2%$1.240$1.265$1.20033,900
$1.235-0.105-7.8%$1.290$1.390$1.15038,100
$1.340-0.030-2.2%$1.420$1.490$1.32014,700
$1.370-0.030-2.1%$1.500$1.500$1.35013,700
$1.400-0.050-3.4%$1.500$1.648$1.38012,100
$1.450-0.170-10.5%$1.620$1.640$1.38040,600
$1.620-0.030-1.8%$1.660$1.760$1.55044,200
$1.650-0.088-5.1%$1.770$1.780$1.61038,700
$1.738-0.112-6.1%$1.800$1.860$1.72039,700
$1.850-0.020-1.1%$1.810$1.900$1.78071,000
$1.870-0.120-6.0%$1.920$1.940$1.81087,600
$1.990-0.120-5.7%$2.130$2.130$1.93050,800
$2.110+0.080+3.9%$2.020$2.180$1.830271,500
$2.030-0.370-15.4%$2.330$2.330$1.830310,500
$2.400+0.200+9.1%$2.530$3.340$2.1602,895,100
$2.200-0.040-1.8%$2.210$2.250$2.13019,600
$2.240+0.056+2.6%$2.180$2.374$2.18030,800
$2.184-0.046-2.1%$2.250$2.270$2.13019,500
$2.230-0.084-3.6%$2.270$2.395$2.04094,000
$2.314-0.081-3.4%$2.350$2.350$2.3005,500
$2.395-0.045-1.8%$2.380$2.600$2.38013,400
$2.440-0.110-4.3%$2.277$2.470$2.27720,600
$2.550+0.050+2.0%$2.520$2.600$2.50014,300
$2.500+0.190+8.2%$2.380$2.650$2.28551,000
$2.310-0.230-9.1%$2.480$2.540$2.14570,800
$2.540+0.010+0.4%$2.500$2.580$2.49014,600
$2.530+0.040+1.6%$2.530$2.600$2.50016,500
$2.490-0.100-3.9%$2.590$2.590$2.45023,800
$2.590-0.020-0.8%$2.660$2.775$2.58024,400
$2.610-0.060-2.2%$2.590$2.750$2.58028,900
$2.670-0.180-6.3%$2.770$2.840$2.60036,900
$2.850+0.120+4.4%$2.730$2.920$2.70072,000
$2.730+0.100+3.8%$2.660$2.760$2.63038,300
$2.630+0.005+0.2%$2.600$2.660$2.56029,000
$2.625+0.065+2.5%$2.540$2.635$2.54021,800
$2.560+0.015+0.6%$2.625$2.690$2.52040,200
$2.545-0.055-2.1%$2.560$2.610$2.54024,400
$2.600-0.220-7.8%$2.820$2.835$2.56086,200
$2.8200.0000.0%$2.920$2.920$2.77016,800
$2.820-0.120-4.1%$2.890$2.945$2.75036,600
$2.940+0.170+6.1%$2.800$2.950$2.72044,200
$2.770-0.140-4.8%$2.870$2.940$2.73091,500
$2.910-0.090-3.0%$3.000$3.000$2.90035,900
$3.000-0.190-6.0%$3.140$3.190$2.90080,900
$3.190-0.260-7.5%$3.510$3.510$3.140119,000
$3.450+0.270+8.5%$3.200$3.640$3.100499,000

Splits

2 splits since 2023 · NASDAQ:VRAX · every price before a split is adjusted for it

DayRatioWhat
1-for-25Consolidation
1-for-10Consolidation
Ticker
NASDAQ:VRAX
Asset type
Stock
Sector
Health care
Industry
Diagnostics & research services
Exchange
NASDAQ
Currency
USD

What changed lately

Latest news

All Virax Biolabs Group Limited news

Virax Biolabs Group Limited on 6ix

Sector
Health care
Industry
Diagnostics & research services
News releases
12 in the last 12 months · 46 in all · newest Oct 29, 2026 · oldest 2022
Decks
4 decks · latest November 2026

Where Virax Biolabs Group Limited is listed

ListingExchangeCountryCurrency
NASDAQ:VRAX · Home listing · This pageNASDAQUnited StatesUSD
BOATS:VRAXBOATSUnited StatesUSD

Valuation

EV/sales −455× against a median of 2.1×: the lowest of 9 Diagnostics & research services companies shown. Statements: Year to Mar 31, 2026 · balance Jun 30, 2026 · price Nov 20, 2026

Enterprise value
−$5.66M USD
P/E
Loss
EV/sales
−455×
EV/EBITDA
Negative EBITDA
Price/book
0.1×
Gross margin
61.9%
Operating margin
Revenue too small
Net margin
Revenue too small
Debt to equity
0.1×
Beta vs S&P 500
1.38

Diagnostics & research services: the 10 companies nearest in size, of 302 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Virax Biolabs Group Limited · NASDAQ:VRAXUS$446,402−US$5.66Mn/a−455×n/a0.1×n/a0.1×1.38
Innovotech Inc. · TSXV:IOTUS$2.66MUS$2.51Mn/a1.0×n/a1.5×−21.1%0.1×0.39
Qlife Holding AB · OMXSTO:QLIFEUS$2.49MUS$2.88Mn/a34.1×n/a9.6×n/a3.1×n/a
Physiomics PLC · LSE:PYCUS$2.46MUS$1.91Mn/a1.6×n/a3.6×−74.1%0.0×n/a
20/20 BioLabs, Inc. · NASDAQ:AIDXUS$2.10M−US$1.01Mn/a−0.5×n/a3.4×−317.8%0.9×1.41
Bluejay Diagnostics, Inc. · NASDAQ:BJDXUS$1.90M−US$5.43Mn/an/an/a0.3×n/a0.0×1.71
Accustem Sciences Inc · OTC:ACUTUS$1.90MUS$1.88Mn/an/an/an/an/an/a0.19
InVitro International · OTC:IVROUS$1.87MUS$644,26029.6×0.8×14.0×1.1×8.2%0.0×0.17
Co-Diagnostics, Inc. · NASDAQ:CODXUS$1.36MUS$2.21Mn/a2.6×n/a0.1×n/a0.2×2.16
Prostatype Genomics AB · OMXSTO:PROGENUS$1.36MUS$1.32Mn/a13.3×n/a2.1×n/a0.0×n/a
Oxurion NV · EURONEXT:OXURUS$254,615US$12.85Mn/a21.1×n/an/a−671.7%n/an/a
Median of the othersUS$1.90MUS$1.90M29.6×2.1×14.0×1.8×−74.1%0.0×0.90

Forecasts

Analysts' consensus from EODHD, read Nov 18, 2026. Not 6ix's view and not investment advice.

Price target
25.00 USD · Analysts' mean
EPS, year to Mar 2027
-6.00 · 1 analyst
Revenue, year to Mar 2027
4K · 1 analyst

Team and board

Officers

OfficerRole
James FosterChairman and Chief Executive Officer

Board

DirectorRole
James FosterChairman and Chief Executive Officer

Events

QuarterResultsShare move
Q2 2026Dec 2, 2025+76.0%
Q1 2026Jul 2, 2025+1.2%
Q2 2025Nov 20, 2024+1.0%
Q1 2023Jul 21, 2022

Open Events

Decks

DeckKindSlidesDate
Investor Presentation (November 2026)Investor deck15 slidesNovember 2026
Investor Presentation (September 2026)Investor deck20 slidesSeptember 2026
Investor Presentation (April 2026)Investor deck16 slidesApril 2026
IPO Roadshow (July 2022)IPO roadshow23 slidesJul 1, 2022

Open Decks

Financings

RaiseDate
Ordinary shares on exercise of preferred investment options
Closed: US$3.3M in the latest tranche · US$6 a share · Warrants at US$6 · H.C. Wainwright & Co.
Dealers: H.C. Wainwright & Co. (lead)
Use of proceeds: Working capital for general corporate purposes
Jul 16, 2026
Private placement of ordinary shares (or pre-funded warrants) and preferred investment options
Closed: US$5M raised · US$0.3999 a share · Warrants at US$0.4 for 60 months · H.C. Wainwright & Co.
Dealers: H.C. Wainwright & Co. (lead)
Use of proceeds: General working capital, extending cash runway into the first half of 2028
Dec 4, 2025

Open Financings · Read by 6ix AI from the company's releases

IPO

Priced at US$5.00 a share on Jul 20, 2022.

Price
US$5.00 a share
Shares offered
3,294,784 ordinary shares · 1,350,000 from the company and 1,944,784 from selling shareholders
Offering size
US$6.8 million
Listing
VRAX on the Nasdaq Capital Market
Underwriters
BOUSTEAD SECURITIES, LLC, VALUABLE CAPITAL LIMITED · In the order on the cover
Shares delivered
On or about Jul 25, 2022

Steps

StepWhen
Draft sent to the SEC in confidenceDec 27, 2021
Filed publiclyMar 18, 2022
Amended 6 timesNewest Jun 27, 2022
Shares registered with an exchangeJun 30, 2022
Declared effective by the SECJun 30, 2022
Final prospectus, with the priceJul 21, 2022

Open IPO · From the cover of the final prospectus (424B4) filed Jul 21, 2022

Financials

Annual, in USD

Income statement

LineFY2026FY2025FY2024FY2023FY2022FY2021FY2020
Revenue12.4K6.33K156.4K8.56K0123.8K99.9K
Cost of revenue4.73K59.4K105.8K9.93K0133.3K54.1K
Gross profit7.69K-53.1K50.6K-1.36K0-9.43K45.7K
Research and development3.74M1.78M1.56M2.18M433.7K120.2K87.0K
Selling, general and administrative2.67M4.33M4.59M5.31M1.29M457.7K602.3K
Operating income-6.40M-6.16M-6.50M-5.73M-1.73M-644.5K-651.2K
Depreciation and amortization439.0K266.6K54.9K00644.5K651.2K
EBITDA-5.96M-5.90M-6.44M-5.73M-1.73M00
Interest expense61.8K58.2K26.9K15.5K15.4K28.6K90.7K
Income before tax-5.93M-6.20M-6.74M-5.46M-1.75M-672.9K-739.5K
Income tax-900.2K-136.7K-194.5K-271-1.77M-666.5K61.7K
Net income-5.02M-6.06M-6.73M-5.46M-1.71M-651.0K-801.1K
Earnings per share, basic-12.64-1.62-3.36-5.13-1.79-14.31-17.61
Earnings per share, diluted-1.62-3.36-5.13-1.79

Balance sheet

LineFY2026FY2025FY2024FY2023FY2022FY2021FY2020
Cash and equivalents6.44M4.23M3.59M9.35M21.8K17.6K22.6K
Short-term investments79.3K94.2K77.3K49.3K6.00K
Receivables30.7K217.8K-24.1K09280
Inventory48.0K94.7K60.4K021.0K21.1K0
Current assets6.83M4.89M4.38M9.63M48.7K39.6K22.6K
Property, plant and equipment1.23M897.6K
Total assets8.32M6.43M5.48M9.81M48.7K39.6K22.6K
Accounts payable51.8K56.1K45.6K159.9K846.5K217.1K212.8K
Current liabilities685.0K673.2K168.8K908.4K1.25M871.4K1.24M
Total debt414.4K377.0K224.3K146.3K3.76K179.5K759.4K
Total liabilities989.8K964.8K345.2K908.4K1.25M871.4K1.24M
Shareholders' equity7.58M5.70M5.37M9.13M-974.6K-650.7K-1.06M
Shares outstanding397.6K4.34M2.57M1.55M9.98M45.5K45.5K

Cash flow

LineFY2026FY2025FY2024FY2023FY2022FY2021FY2020
Cash from operations-4.62M-4.56M-6.25M-4.18M-809.1K-590.2K-744.6K
Capital spending-255.8K-603.9K-952.5K-178.4K000
Free cash flow-4.88M-5.17M-7.20M-4.36M-809.1K-590.2K-744.6K
Cash from investing-255.8K-603.9K-1.16M-178.4K-178.4K-178.4K-178.4K
Cash from financing7.09M5.81M1.65M13.7M813.2K585.2K704.6K
Change in cash2.21M639.7K-5.76M9.33M4.13K-4.99K-40.0K

Open Financials

Filings

FilingDateTypeFiled with
6-K · Report of a foreign issuerNov 18, 2026Current reportSEC
6-K · Report of a foreign issuerNov 13, 2026Current reportSEC
6-K · Report of a foreign issuerOct 29, 2026Current reportSEC
3 · Initial statement of ownershipOct 21, 2026Insider tradeSEC
6-K · Report of a foreign issuerOct 9, 2026Current reportSEC
424B3 · ProspectusSep 9, 2026Offer documentSEC
6-K · Report of a foreign issuerSep 4, 2026Current reportSEC
424B5 · ProspectusSep 4, 2026Offer documentSEC
EFFECT · Notice that a registration is effectiveSep 4, 2026Other filingsSEC
F-3/A · Registration statement, amendedSep 2, 2026Offer documentSEC
All 161 filings
FilingDateTypeFiled with
6-K · Report of a foreign issuerAug 26, 2026Current reportSEC
6-K · Report of a foreign issuerAug 18, 2026Current reportSEC
6-K · Report of a foreign issuerJul 31, 2026Current reportSEC
F-3 · Registration statementJul 24, 2026Offer documentSEC
6-K · Report of a foreign issuerJul 16, 2026Current reportSEC
6-K · Report of a foreign issuerJul 10, 2026Current reportSEC
6-K · Report of a foreign issuerJul 9, 2026Current reportSEC
20-F · Annual reportJul 2, 2026Annual reportSEC
6-K · Report of a foreign issuerJun 24, 2026Current reportSEC
6-K · Report of a foreign issuerJun 12, 2026Current reportSEC
6-K · Report of a foreign issuerMay 26, 2026Current reportSEC
6-K · Report of a foreign issuerMay 22, 2026Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2026Big-stake noticeSEC
6-K · Report of a foreign issuerApr 14, 2026Current reportSEC
6-K · Report of a foreign issuerApr 10, 2026Current reportSEC
3 · Initial statement of ownershipMar 31, 2026Insider tradeSEC
3 · Initial statement of ownershipMar 20, 2026Insider tradeSEC
6-K · Report of a foreign issuerMar 18, 2026Current reportSEC
3 · Initial statement of ownershipMar 18, 2026Insider tradeSEC
3 · Initial statement of ownershipMar 18, 2026Insider tradeSEC
3 · Initial statement of ownershipMar 18, 2026Insider tradeSEC
3 · Initial statement of ownershipMar 18, 2026Insider tradeSEC
SCHEDULE 13G · Big-stake noticeFeb 17, 2026Big-stake noticeSEC
6-K · Report of a foreign issuerJan 30, 2026Current reportSEC
424B3 · ProspectusDec 31, 2025Offer documentSEC
EFFECT · Notice that a registration is effectiveDec 31, 2025Other filingsSEC
CORRESP · Letter to the SECDec 29, 2025Other filingsSEC
F-3 · Registration statementDec 18, 2025Offer documentSEC
DDec 18, 2025Other filingsSEC
6-K · Report of a foreign issuerDec 4, 2025Current reportSEC
6-K · Report of a foreign issuerDec 2, 2025Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedOct 29, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedOct 29, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedOct 29, 2025Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeOct 29, 2025Big-stake noticeSEC
6-K · Report of a foreign issuerJul 30, 2025Current reportSEC
20-F · Annual reportJul 2, 2025Annual reportSEC
6-K · Report of a foreign issuerJun 13, 2025Current reportSEC
6-K · Report of a foreign issuerMar 18, 2025Current reportSEC
6-K · Report of a foreign issuerMar 13, 2025Current reportSEC
6-K · Report of a foreign issuerMar 5, 2025Current reportSEC
6-K · Report of a foreign issuerFeb 25, 2025Current reportSEC
S-8 · Registration statement for employee plansJan 30, 2025Offer documentSEC
6-K · Report of a foreign issuerDec 23, 2024Current reportSEC
6-K · Report of a foreign issuerDec 17, 2024Current reportSEC
6-K · Report of a foreign issuerDec 10, 2024Current reportSEC
6-K · Report of a foreign issuerNov 20, 2024Current reportSEC
SC 13G/A · Big-stake notice, amendedNov 14, 2024Big-stake noticeSEC
6-K · Report of a foreign issuerOct 31, 2024Current reportSEC
6-K · Report of a foreign issuerOct 23, 2024Current reportSEC
6-K · Report of a foreign issuerSep 30, 2024Current reportSEC
424B5 · ProspectusSep 30, 2024Offer documentSEC
6-K · Report of a foreign issuerAug 23, 2024Current reportSEC
424B5 · ProspectusAug 23, 2024Offer documentSEC
20-F · Annual reportAug 20, 2024Annual reportSEC
NT 20-FAug 1, 2024Explanation requestSEC
6-K · Report of a foreign issuerJun 11, 2024Current reportSEC
6-K · Report of a foreign issuerApr 25, 2024Current reportSEC
6-K · Report of a foreign issuerApr 16, 2024Current reportSEC
6-K · Report of a foreign issuerMar 15, 2024Current reportSEC
SC 13G · Big-stake noticeFeb 14, 2024Big-stake noticeSEC
6-K · Report of a foreign issuerJan 22, 2024Current reportSEC
424B5 · ProspectusJan 22, 2024Offer documentSEC
6-K · Report of a foreign issuerJan 12, 2024Current reportSEC
6-K · Report of a foreign issuerDec 21, 2023Current reportSEC
424B3 · ProspectusDec 20, 2023Offer documentSEC
6-K · Report of a foreign issuerDec 20, 2023Current reportSEC
424B3 · ProspectusDec 20, 2023Offer documentSEC
6-K · Report of a foreign issuerDec 18, 2023Current reportSEC
EFFECT · Notice that a registration is effectiveDec 18, 2023Other filingsSEC
6-K · Report of a foreign issuerDec 14, 2023Current reportSEC
CORRESP · Letter to the SECDec 13, 2023Other filingsSEC
UPLOAD · Letter from the SECDec 12, 2023Other filingsSEC
6-K · Report of a foreign issuerDec 8, 2023Current reportSEC
F-3 · Registration statementDec 5, 2023Offer documentSEC
6-K · Report of a foreign issuerNov 8, 2023Current reportSEC
6-K · Report of a foreign issuerOct 31, 2023Current reportSEC
DOct 17, 2023Other filingsSEC
6-K · Report of a foreign issuerOct 12, 2023Current reportSEC
6-K · Report of a foreign issuerOct 4, 2023Current reportSEC
6-K · Report of a foreign issuerSep 12, 2023Current reportSEC
6-K · Report of a foreign issuerSep 1, 2023Current reportSEC
6-K · Report of a foreign issuerAug 3, 2023Current reportSEC
6-K · Report of a foreign issuerJul 18, 2023Current reportSEC
20-F · Annual reportJun 14, 2023Annual reportSEC
6-K · Report of a foreign issuerJun 14, 2023Current reportSEC
6-K · Report of a foreign issuerMay 4, 2023Current reportSEC
6-K · Report of a foreign issuerApr 21, 2023Current reportSEC
6-K · Report of a foreign issuerApr 19, 2023Current reportSEC
424B3 · ProspectusMar 31, 2023Offer documentSEC
EFFECT · Notice that a registration is effectiveMar 31, 2023Other filingsSEC
CORRESP · Letter to the SECMar 28, 2023Other filingsSEC
UPLOAD · Letter from the SECMar 28, 2023Other filingsSEC
F-1 · Registration statementMar 22, 2023Offer documentSEC
DMar 15, 2023Other filingsSEC
6-K · Report of a foreign issuerMar 10, 2023Current reportSEC
6-K · Report of a foreign issuerMar 7, 2023Current reportSEC
6-K · Report of a foreign issuerFeb 7, 2023Current reportSEC
6-K · Report of a foreign issuerFeb 2, 2023Current reportSEC
6-K · Report of a foreign issuerFeb 2, 2023Current reportSEC
6-K · Report of a foreign issuerJan 4, 2023Current reportSEC
6-K · Report of a foreign issuerDec 6, 2022Current reportSEC
424B3 · ProspectusDec 2, 2022Offer documentSEC
EFFECT · Notice that a registration is effectiveDec 2, 2022Other filingsSEC
CORRESP · Letter to the SECNov 29, 2022Other filingsSEC
UPLOAD · Letter from the SECNov 25, 2022Other filingsSEC
F-1 · Registration statementNov 18, 2022Offer documentSEC
6-K · Report of a foreign issuerNov 18, 2022Current reportSEC
6-K · Report of a foreign issuerNov 15, 2022Current reportSEC
6-K · Report of a foreign issuerNov 8, 2022Current reportSEC
6-K · Report of a foreign issuerNov 3, 2022Current reportSEC
6-K · Report of a foreign issuerOct 26, 2022Current reportSEC
6-K · Report of a foreign issuerSep 22, 2022Current reportSEC
6-K · Report of a foreign issuerSep 20, 2022Current reportSEC
6-K · Report of a foreign issuerSep 12, 2022Current reportSEC
6-K · Report of a foreign issuerSep 7, 2022Current reportSEC
20-F · Annual reportAug 12, 2022Annual reportSEC
NT 20-FJul 29, 2022Explanation requestSEC
6-K · Report of a foreign issuerJul 29, 2022Current reportSEC
6-K · Report of a foreign issuerJul 26, 2022Current reportSEC
424B4 · ProspectusJul 21, 2022Offer documentSEC
CERT · Exchange's certificate of listingJul 20, 2022Other filingsSEC
EFFECT · Notice that a registration is effectiveJul 1, 2022Other filingsSEC
FWP · Free writing prospectusJun 30, 2022Offer documentSEC
FWP · Free writing prospectusJun 30, 2022Offer documentSEC
8-A12B · Registration of shares for listing on an exchangeJun 30, 2022Other filingsSEC
CORRESP · Letter to the SECJun 28, 2022Other filingsSEC
CORRESP · Letter to the SECJun 28, 2022Other filingsSEC
CORRESP · Letter to the SECJun 24, 2022Other filingsSEC
F-1/A · Registration statement, amendedJun 24, 2022Offer documentSEC
UPLOAD · Letter from the SECJun 24, 2022Other filingsSEC
CORRESP · Letter to the SECJun 24, 2022Other filingsSEC
F-1/A · Registration statement, amendedJun 24, 2022Offer documentSEC
UPLOAD · Letter from the SECJun 23, 2022Other filingsSEC
CORRESP · Letter to the SECJun 21, 2022Other filingsSEC
F-1/A · Registration statement, amendedJun 21, 2022Offer documentSEC
UPLOAD · Letter from the SECJun 16, 2022Other filingsSEC
F-1/A · Registration statement, amendedJun 6, 2022Offer documentSEC
CORRESP · Letter to the SECMay 11, 2022Other filingsSEC
F-1/A · Registration statement, amendedMay 11, 2022Offer documentSEC
UPLOAD · Letter from the SECMay 5, 2022Other filingsSEC
CORRESP · Letter to the SECApr 22, 2022Other filingsSEC
F-1/A · Registration statement, amendedApr 22, 2022Offer documentSEC
UPLOAD · Letter from the SECApr 7, 2022Other filingsSEC
CORRESP · Letter to the SECMar 18, 2022Other filingsSEC
F-1 · Registration statementMar 18, 2022Offer documentSEC
UPLOAD · Letter from the SECMar 10, 2022Other filingsSEC
DRSLTR · Letter to the SEC with a draftFeb 17, 2022Other filingsSEC
DRS/A · Draft registration statement, amendedFeb 17, 2022Offer documentSEC
UPLOAD · Letter from the SECJan 28, 2022Other filingsSEC
DRS · Draft registration statementDec 27, 2021Offer documentSEC

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Virax Biolabs Group Limited’s releases · as of Jul 16, 2026

Common shares
1,344,988
Fully diluted
1,344,988

Fully diluted

LineShares
Common shares1,344,988

Warrants and options

Lot
Warrants · US$6.00 · expiry not stated
Warrants · US$0.40 · expire about Dec 2030

Share count over time

CountShares
Nov 22, 20261,344,988
Jun 24, 2026

Open Cap table

Shareholders

StakeStakeSharesDateFiling
James Foster24.90%288KDec 31, 2022Schedule 13G

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Nelson M Haight
Other companies: Mountain Crest Acquisition 6 Corp. (Director · Since at least Apr 29, 2026); Team, Inc. (Chief Financial Officer · Since at least Jun 13, 2022); Key Energy Services Inc (Chief Financial Officer · Jun 15, 2020 – Jun 15, 2020 · Past); Playboy, Inc. (Director · Jun 4, 2020 – Jun 4, 2020 · Past); Amplify Energy Corp. (EVP and CFO · Apr 19, 2012 – Apr 21, 2017 · Past)
Director · Since at least Mar 18, 2026
Jason D. Davis
Other companies: FibroBiologics, Inc. (Chief Financial Officer · Since at least Jun 9, 2025); Particle Drilling Technologies Inc (Interim Chief Financial Office · Jan 5, 2009 – Apr 17, 2009 · Past)
Chief Financial Officer · Since at least Mar 18, 2026
Evan Michael NortonDirector · Since at least Mar 18, 2026
Iain David MillerDirector · Since at least Mar 18, 2026
James FosterChairman and Chief Executive Officer · Since at least Dec 3, 2025
Nigel William McCrackenChief Operating Officer, Director · Since at least Mar 18, 2026

Open People

Log in to ask 6ix AI your own questions about Virax Biolabs Group Limited.